Glycovax Pharma Inc.
Glycovax Pharma is a biopharmaceutical company specializing in the development of innovative carbohydrate-based vaccines. Founded in 2016 in Montreal, Canada, it leverages glycoimmunology and cutting-edge technology to create effective solutions for viral, bacterial, and cancer infections. The company aims to advance science and empower health by designing next-generation vaccines using synthetic antigens, customizable linkers, and novel adjuvants.
Industries
Nr. of Employees
small (1-50)
Glycovax Pharma Inc.
424, Guy street, suite 202 Montréal (Quebec) Canada H3J 1S6
Products
CRM197 carrier protein (R&D and GMP grades)
High-quality, scalable CRM197 carrier protein produced in multiple quality grades to support conjugate vaccine development and regulatory filings.
Synthetic sulfated lactosyl archaeol (SLA) adjuvant (R&D and planned GMP)
A fully synthetic adjuvant designed to produce balanced humoral and cellular immune responses, increase antibody production and reduce required antigen dose; planned for GMP production.
CRM197 carrier protein (R&D and GMP grades)
High-quality, scalable CRM197 carrier protein produced in multiple quality grades to support conjugate vaccine development and regulatory filings.
Synthetic sulfated lactosyl archaeol (SLA) adjuvant (R&D and planned GMP)
A fully synthetic adjuvant designed to produce balanced humoral and cellular immune responses, increase antibody production and reduce required antigen dose; planned for GMP production.
Services
Collaborative vaccine design and development services covering target selection, synthetic antigen design, linker optimization, immunogen engineering, candidate selection and preclinical efficacy assessments.
Services from immunogen preparation through antibody generation, screening, engineering and preclinical development for therapeutic antibody programs.
Supply of carrier protein and adjuvant materials in R&D and GMP grades for use in conjugate vaccine development and regulatory submissions.
Process transfer and scale-up services including process validation activities to transition vaccine components from research to commercial manufacturing.
Collaborative vaccine design and development services covering target selection, synthetic antigen design, linker optimization, immunogen engineering, candidate selection and preclinical efficacy assessments.
Services from immunogen preparation through antibody generation, screening, engineering and preclinical development for therapeutic antibody programs.
Supply of carrier protein and adjuvant materials in R&D and GMP grades for use in conjugate vaccine development and regulatory submissions.
Process transfer and scale-up services including process validation activities to transition vaccine components from research to commercial manufacturing.
Expertise Areas
- Conjugate vaccine design and development
- Glycoimmunology and glycochemistry
- Synthetic carbohydrate antigen synthesis
- Adjuvant chemistry and immunostimulant design
Key Technologies
- Synthetic carbohydrate antigen synthesis
- Glycoconjugate vaccine platforms
- Linker/conjugation chemistry
- Carrier protein production (CRM197)
News & Updates
Glycovax Pharma will participate in the BIO International Convention from June 16 to 19, 2025, at the Boston Convention and Exhibition Center, engaging with industry leaders in biotech.
Glycovax Pharma has begun large-scale biomanufacturing of CRM197 protein for use in conjugate vaccines for humans and animals, with a system developed by the NRC.
Glycovax Pharma will participate in the BIO International Convention from June 16 to 19, 2025, at the Boston Convention and Exhibition Center, engaging with industry leaders in biotech.
Glycovax Pharma has begun large-scale biomanufacturing of CRM197 protein for use in conjugate vaccines for humans and animals, with a system developed by the NRC.